Adaptive Biotechnologies (ADPT) Change in Receivables (2018 - 2026)

Adaptive Biotechnologies has reported Change in Receivables for 9 years, with the latest figure at -$2.0 million in Q1 2026.

• Quarterly Change in Receivables fell 209.98% year-over-year to -$2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (up 204.11% YoY) and the FY2025 annual result came in at $8.6 million, up 130.93% from the prior year.
• Change in Receivables slipped to -$2.0 million in Q1 2026 per ADPT's latest filing, from $5.5 million in the prior quarter.
• Over five years, Change in Receivables peaked at $13.5 million in Q4 2022 and troughed at -$9.1 million in Q1 2023.
• A 5-year average of $1.8 million and a median of $1.2 million in 2022 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2022 and 2024: Change in Receivables soared 4606.97% in 2022, then slumped 1132.37% in 2024.
• Over 5 years, Change in Receivables stood at $13.5 million in 2022, then slumped by 49.91% to $6.8 million in 2023, then tumbled by 86.71% to $899000.0 in 2024, then soared by 516.69% to $5.5 million in 2025, then slumped by 136.98% to -$2.0 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered -$2.0 million, $5.5 million, and $536000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.